

Bernadett Szabados

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11227800/publications.pdf>

Version: 2024-02-01

21
papers

782
citations

933447

10
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

1427
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	30.7	407
2	Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. <i>European Urology</i> , 2018, 73, 149-152.	1.9	93
3	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	1.9	56
4	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , 2020, 77, 269-276.	1.9	45
5	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	6.4	39
6	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	1.9	39
7	Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>European Urology</i> , 2020, 78, 276-280.	1.9	20
8	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	5.4	18
9	Adverse effects and radiological manifestations of new immunotherapy agents. <i>British Journal of Radiology</i> , 2019, 92, 20180164.	2.2	14
10	Cytoreductive nephrectomy in the current treatment algorithm. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987902.	3.2	13
11	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. <i>European Urology Oncology</i> , 2021, 4, 943-947.	5.4	11
12	Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. <i>European Urology Oncology</i> , 2019, 4, 659-662.	5.4	9
13	Emphysematous pyelonephritis: Case report and literature overview. <i>Urologia</i> , 2018, 85, 123-126.	0.7	8
14	Partial Nephrectomy in pT3a Tumors Less Than 7 cm in Diameter Has a Superior Overall Survival Compared to Radical Nephrectomy. <i>Cureus</i> , 2019, 11, e5781.	0.5	4
15	Metastatic papillary renal cell carcinoma in the era of targeted therapy – a retrospective study from three European academic centres. <i>Acta Oncologica</i> , 2019, 58, 306-312.	1.8	3
16	Survival of patients with papillary type II renal cell carcinoma treated with tyrosine-kinase inhibitors: A comparison with clear cell histologies. <i>Journal of Clinical Oncology</i> , 2014, 32, 511-511.	1.6	1
17	Avelumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	2.4	1
18	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al.'s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. <i>European Urology</i> , 2021, 79, e20-e21.	1.9	0

#	ARTICLE	IF	CITATIONS
19	Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.07.007 . <i>European Urology</i> , 2021, 79, e26-e27.	1.9	0
20	Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 514-514.	1.6	0
21	High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 377-377.	1.6	0